retatrutide trial results news today This is exciting. 👀 The TRIUMPH-4 for Lilly's investigational medication were released, showing weight loss of up to 71 lbs (~28%) over 68 weeks in the highest-dose group—far beyond Eli Lilly retatrutide Phase 3

Many people wonder about this after seeing ads for these products

Nausea, the most common side effect occurring in 15-30% of patients depending on dose, typically peaks during the first few weeks after dose initiation or escalation and often improves with continued use

In contrast, GLP-1 receptor agonists approved by the FDAincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound, which also activates GIP receptors)are modified to resist DPP-4 degradation

Keerie, A

L.HolstJ

The Estonian Biobank Research Team responsible for data collection, genotyping, QC and imputation: A